Benzinga | Jul 27, 2021 11:13AM EDT

AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

All-stock transaction maintains AC Immune's strong cash position



USD 25 million private placement led by premier investor Athos Service GmbH

Transactions expand and accelerate AC Immune's therapeutic development in Parkinson's disease

AC Immune to immediately launch clinical development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson's disease

Conference call scheduled today at 8:30 am ET / 2:30 pm CET